This scenario should be further investigated; if confirmed, it would be intriguing to investigate the clinical potential of lifitegrast, an FDA-approved anti-LFA-1 drug that treats ocular inflammation (https://medlineplus.gov/druginfo/meds/a616039.html) (accessed on 15 December 2022) [78], in preventing or hindering NSCLC or other cancers’ immune evasion. This evidence concerns the gene ITGB2 and cancer.